secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMMUCELL CORP /DE/ (ICCC)
CIK:        0000811641
Form:       8-K
Filed at:   2024-12-02T23:59:59+00:00
Accession:  0001213900-24-104543
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ImmuCell amends Norbrook agreement; termination March 31, 2026 if FDA approval not received by Feb 28, 2026
--------------------------------------------------------------------------------

- Norbrook will complete manufacture of current in-process inventory.
- Agreement terminates March 31, 2026, subject to terms.
- If FDA approval for Re-Tain not received by Feb 28, 2026, agreement expires and Norbrook invoices Final Balance.
- Amendment continues other terms of the Development Services and Commercial Supply Agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/811641/000121390024104543/0001213900-24-104543-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/811641/000121390024104543/ea0223315-8k_immu.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-104543

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer